Patents Examined by Charanjit S. Aulakh
  • Patent number: 7799918
    Abstract: An organic metal complex is provided. The organic metal complex has formula (I): wherein R1 includes hydrogen, C1˜C9 alkyl, C5˜C8 cycloalkyl, or substituted or non-substituted aromatic groups, R2 and R3 comprise hydrogen, fluorine, trifluoromethyl, C1˜C9 alkyl, C5˜C8 cycloalkyl, or substituted or non-substituted aromatic groups, Y comprises C—R or carbonyl, wherein R comprises hydrogen, C1˜C9 alkyl, C5˜C8 cycloalkyl, or substituted or non-substituted aromatic groups, L is a ligand, M comprises iridium, platinum, ruthenium, gold, or palladium, m is 1˜3, and n is 0˜2, wherein m+n is equal to the valence of M.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: September 21, 2010
    Assignee: Industrial Technology Research Institute
    Inventors: Chih-Lung Chin, Wan Chi Chen, Kung-Lung Cheng
  • Patent number: 7799798
    Abstract: This invention is directed to spiroheterocyclic compounds of formula (I) wherein k, j, p, Q, R1, R3a, R3b, R3c, and R3d are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: April 11, 2006
    Date of Patent: September 21, 2010
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Mikhail Chafeev, Sultan Chowdhury, Robert Fraser, Jianmin Fu, Rajender Kamboj, Shifeng Liu, Mehran Seid Bagherzadeh, Jianyu Sun, Serguei Sviridov
  • Patent number: 7799919
    Abstract: The invention relates to novel perylenetetracarboxdiimide derivatives with improved performance properties.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: September 21, 2010
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Christopher Kohl, Jianqiang Qu, Klaus Müllen
  • Patent number: 7799920
    Abstract: A process for preparing perylene-3,4-dicarboximides which bear a sterically demanding substituent on the imide nitrogen atom by reacting a perylene-3,4:9,10-tetracarboxylic dianhydride with a sterically hindered primary amine in a substantially anhydrous reaction medium, which comprises undertaking the reaction in the presence of a tertiary amine, of a solvent based on a cyclic imine or amide and of a Lewis acid as a catalyst.
    Type: Grant
    Filed: November 4, 2005
    Date of Patent: September 21, 2010
    Assignee: BASF Aktiengesellschaft
    Inventors: Martin Koenemann, Peter Blaschka, Helmut Reichelt
  • Patent number: 7799917
    Abstract: A charge-neutral organometallic dendrimer is described, said dendrimer having the formula (I): CORE-[DENDRITE(-Q)a]n??(I) in which CORE represents a group of formula MXxYz, in which M represents a metal cation, x represents an integer of 1 or more, each X which may be the same or different represents a mono-, bi- or tri-dentate coordinating group, z represents 0 or an integer of 1 or more, and each Y which may be the same or different represents a coordinating group, the total of (b.x)+(c.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: September 21, 2010
    Assignees: Isis Innovation Limted, The University Court of the University of St. Andrews
    Inventors: Ifor David William Samuel, Paul Leslie Burn, Shih-Chun Lo
  • Patent number: 7795299
    Abstract: Compounds of Formulas I-II are described, along with methods of using such compounds for the treatment of cancer and pharmaceutical formulations thereof.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: September 14, 2010
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Kuo-Hsiung Lee, Xihong Wang, Kenneth F. Bastow, Tian-Shung Wu
  • Patent number: 7795434
    Abstract: Alkaloid reaction products obtainable in a process wherein alkaloids are reacted with an alkylating agent, preferably thiotepa, whereafter unreacted alkylating agent and other water-soluble compounds are removed from the reaction mixture by washing with water or a suitable aqueous solvent, whereafter the reaction mixture is subjected to a treatment with strong acid, preferably hydrogen chloride (HCl), to precipitate a water soluble salt of the reaction products. The precipitated reaction products comprise at least one quaternary alkaloid derivative and are suitable as drugs for prophylactic or therapeutic application, particularly in the treatment of immunological or metabolic dysfunctions, and cancer.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: September 14, 2010
    Inventor: Wassyl Nowicky
  • Patent number: 7795281
    Abstract: The optically active compound (R)-2-amino-1,4-dihydro-6-methyl-4-(3 -nitrophenyl)-3,5-pyridinedicarboxylic acid 3-(1-diphenylmethylazetidin-3-yl) ester 5 -isopropyl ester or a pharmacologically acceptable salt thereof, and a method using the compound or its salt to treat circulatory diseases.
    Type: Grant
    Filed: June 24, 2008
    Date of Patent: September 14, 2010
    Assignees: Daiichi Sankyo Company, Limited, Ube Industries, Ltd.
    Inventors: Takashi Kobayashi, Toshio Sada
  • Patent number: 7795433
    Abstract: A method for preparing a perylene pigment or perinone pigment involves a condensation reaction between perylene tetracarboxylic acid or naphthalene tetracarboxylic acid, or anhydrides or imides thereof, and amines in the presence of certain metal catalysts, such as ammonium molybdate, molybdenum oxide, and metal carbonyls, such as hexacarbonylmolybdenum, titanium carbonyl, iron carbonyls, and the like. The use of these catalysts provides various advantages, including the reduction of the amount of the catalyst, while achieves high yields, the lowering of reaction temperatures, and the reduction of insoluble sludge in the reaction mixture, thereby making the reaction operation easier and reducing the amounts of hazardous wastes containing heavy metals.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: September 14, 2010
    Assignee: Sun Chemical Corporation
    Inventor: Thomas Flatt
  • Patent number: 7795432
    Abstract: The invention relates to novel perylenetetracarboxylic acid bisimide derivatives with improved performance properties.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: September 14, 2010
    Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Christopher Kohl, Jianqiang Qu, Klaus Müllen
  • Patent number: 7790889
    Abstract: Disclosed herein are a di-(4-vinylpyridine) metal phthalocyanine compound in which 4-vinylpyridines as ligands are included in a phthalocyanine having a metal, a composition comprising the same and a preparation method thereof. The di-(4-vinylpyridine) metal phthalocyanine compound has an excellent UV blocking effect together with low surface resistance and is prepared but by charging a powder phase with nitrogen, not by dissolving raw materials in an organic solvent as in the prior art.
    Type: Grant
    Filed: December 24, 2008
    Date of Patent: September 7, 2010
    Assignee: Hoseo University Academic Cooperation Foundation
    Inventors: Young Goo Kang, Dae Woo Ihm, Shi Surk Kim
  • Patent number: 7790980
    Abstract: A dye for a dye sensitized photovoltaic cell is disclosed. A dye sensitized photovoltaic cell including the dye is also disclosed. The dye includes a metal composite treated with a cation selected from imidazolium cations, pyridinium cations, pyrrolidinium cations, and quinolidinium cations.
    Type: Grant
    Filed: August 17, 2006
    Date of Patent: September 7, 2010
    Assignee: Samsung SDI Co., Ltd.
    Inventors: Jae-Kwan Lee, Ji-Won Lee, Wha-Sup Lee, Kwang-Soon Ahn, Jae-Man Choi, Moon-Sung Kang, Byong-Cheol Shin, Joung-Won Park, Moon-Seok Kwon, Soo-Jin Moon
  • Patent number: 7786134
    Abstract: Lipophilic anticancer drug compounds, compositions that include the compounds, and methods for treating a cell proliferative disease using the compounds.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: August 31, 2010
    Assignee: Sonus Pharmaceuticals, Inc.
    Inventors: Yuehua Zhang, Lynn C. Gold
  • Patent number: 7786164
    Abstract: Lipophilic di(anticancer drug) compounds, compositions that include the compounds, and methods for treating a cell proliferative disease using the compounds.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: August 31, 2010
    Assignee: Sonus Pharmaceuticals, Inc.
    Inventors: Yuehua Zhang, Lynn C. Gold
  • Patent number: 7786097
    Abstract: The present invention is directed to compounds of Formula I: or salt thereof, which are modulators of the glucocorticoid receptor. The compounds and salts of the invention are useful in the treatment of conditions mediated by glucocorticoid receptor activity.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: August 31, 2010
    Assignee: Pfizer Inc.
    Inventors: Hengmiao (Henry) Cheng, Rajesh Devraj, Gary A Decresenzo, Xiao Hu, Kevin D. Jerome, Mark Obukowicz, Lisa Olson, Paul V. Rucker, Ronald Keith Webber
  • Patent number: 7786161
    Abstract: A carboxylic acid derivative of formula (I): wherein R1 is —COOH, —COOR6, etc.; A is a single bond, alkylene, etc.; R2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE2 receptor, especially subtypes EP3 and/or EP4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.
    Type: Grant
    Filed: October 27, 2008
    Date of Patent: August 31, 2010
    Assignee: ONO Pharmaceutical Co., Ltd.
    Inventors: Kousuke Tani, Masaki Asada, Kaoru Kobayashi, Masami Narita, Mikio Ogawa
  • Patent number: 7781445
    Abstract: Substituted indenoisoquinolinium compounds, and pharmaceutical formulations of substituted indenoisoquinolinium compounds are described. Also described are processes for preparing substituted indenoisoquinolinium compounds. Also described are methods for treating cancer in mammals using the described substituted indenoisoquinolinium compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: August 24, 2010
    Assignees: Purdue Research Foundation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Mark S. Cushman, Alexandra S. Ioanoviciu, Yves G. Pommier
  • Patent number: 7781443
    Abstract: A novel compound of the formula (I): wherein R1 is alkoxycarbonyl or the like, R2 is alkyl or the like; R3 is hydrogen or the like; R4 is alkylene or the like; R5 is optionally substituted heterocyclic group; R6, R7, and R8 are independently hydrogen; alkyl, alkoxy, or the like; R10 is optionally substituted aromatic ring, or the like; or a pharmaceutically acceptable salt thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP).
    Type: Grant
    Filed: September 27, 2006
    Date of Patent: August 24, 2010
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Hitoshi Kubota, Yoshinori Nakamura, Takanori Higashijima, Yasuo Yamamoto, Kozo Oka, Shigeki Igarashi
  • Patent number: 7776875
    Abstract: There are provided compounds of the formula and pharmaceutically acceptable salts and esters and enantiomers thereof wherein W, X, X?, Y, V, V?, A, B and R are as described herein. The compounds have utility as antiproliferative agents, especially, as anticancer agents.
    Type: Grant
    Filed: November 18, 2008
    Date of Patent: August 17, 2010
    Assignee: Hoffman-La Roche Inc.
    Inventors: Li Chen, Xingchun Han, Yun He, Song Yang, Zhuming Zhang
  • Patent number: 7776889
    Abstract: Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein An, En, Mn, Un, Gn, Jn, Kn, R9, R10, R11, R32, R33, B and Het are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: August 17, 2010
    Assignee: Schering Corporation
    Inventors: Samuel Chackalamannil, Mariappan V. Chelliah, Yan Xia